Reduction in levels of @entity19579 by @entity1780 treatment in XXXX with @entity195 .

@entity1 @entity353 @entity3413 @entity2204 @entity2299 @entity37793 @entity1670 @entity33349 @entity5753 @entity1780 @entity3150 @entity19579 @entity19411 @entity195 @entity413 @entity3645 @entity8673 @entity165 @entity9543
BACKGROUND: The statin treatment of @entity2299 is associated with a reduced risk of development of @entity195 ( @entity195 ). The effect may be mediated by a reduction in @entity165 biosynthesis in the brain, by lowering levels of @entity2204 ( @entity2204 )-containing lipoproteins, or by pleitropic effects such as @entity353 . In the brain, @entity165 from damaged or dying neurons is converted to @entity19579 by @entity165 24-hydroxylase ( @entity33349 ). The @entity19411 is subsequently transferred across the blood-brain barrier, transported to the liver by low-density lipoproteins (LDLs), and excreted as @entity3645 . Most of plasma @entity19579 is derived from brain @entity165 ; consequently, plasma levels of the @entity19411 reflect brain @entity165 catabolism. OBJECTIVE: To examine the effect of 3 statins and a nonstatin hypolipidemic agent on plasma levels of @entity19579 and @entity2204 in @entity1 with @entity195 . STUDY DESIGN: The study had a sequential parallel design. It was open-labeled and involved lipoprotein and @entity19579 evaluations at baseline and at 6 weeks of treatment with 40 mg of @entity5753 , @entity3413 , or @entity8673 per day, or 1 g of extended-release niacin per day. Blood samples were drawn after a 12-hour fast for measurement of plasma @entity3150 , @entity19411 , lipoprotein @entity165 , and levels of @entity2204 , plasma transaminases, and @entity413 . Measurements were made at baseline and during treatment. RESULTS: @entity1780 treatment reduced levels of plasma @entity37793 by 49.5%, @entity19579 by 21.4%, LDL @entity165 by 34.9%, and total @entity165 by 25%. The ratios of @entity37793 - @entity9543 and @entity19579 -LDL @entity165 were reduced significantly, but the ratio of @entity19579 -total @entity165 was unchanged. Extended-release @entity1670 also significantly reduced levels of @entity19579 by 10% and LDL @entity165 by 18.1%. None of the agents lowered plasma concentration of @entity2204 . CONCLUSIONS: Statins lowered levels of plasma @entity19579 without affecting levels of @entity2204 . The LDL lowering was more pronounced than @entity19579 reductions. The effect of statins on LDL partially explains the reduction of plasma @entity19411 level.
